Feasibility of Fast Turnaround Genetic Screening for Type 1 Diabetes Risk in Newborns – Recruiting Infants for the Global Platform for the Prevention of Autoimmune Diabetes Primary Prevention Study Supplementation with B ifidobacterium infantis for Mitigation of Type 1 Diabetes Autoimmunity
Machbarkeit eines schnellen genetischen Screenings auf Typ-1-Diabetes-Risiko bei Neugeborenen – Rekrutierung von Säuglingen für die Global Platform for the Prevention of Autoimmune Diabetes Primary Prevention Study Supplementation with B. infantis for Mitigation of Type 1 Diabetes Autoimmunity
Hormone and Metabolic Research · 01.10.2026 · 58 (10) · 391-398
DOI: 10.1055/a-2960-5380 ↗Auf einen Blick
Bei 257.784 Neugeborenen ermöglichte ein beschleunigtes Screening die Rekrutierung in eine Interventionsstudie. 1.149 eligible Säuglinge wurden eingeschlossen; die Schritte lagen median innerhalb der ersten 6 Lebenswochen.
Fragestellung
Ist ein schnelles genetisches Screening bei Neugeborenen machbar, um Säuglinge mit erhöhtem Typ-1-Diabetes-Risiko rechtzeitig für eine Präventionsstudie einzuschließen?
Methode
Screening- und Rekrutierungsbeschreibung in Belgien, Deutschland, Polen, Schweden und dem Vereinigten Königreich.
Ergebnisse
Von 257.784 gescreenten Neugeborenen hatten 3.309 (1,3 %) einen geeigneten Genotyp. Probenentnahme, Registrierung, Genotypisierung, validierte Ergebnisse, Beratung und Einschluss erfolgten median an Tag 2, 9, 21, 22, 29 und 38.
Schlussfolgerung der Autor:innen
Die Autor:innen zeigen die Machbarkeit beschleunigter genetischer Screening-Programme und dass Neugeborenen-Screening-Workflows innerhalb der ersten 6 Lebenswochen abgeschlossen werden können, um den rechtzeitigen Einschluss in Frühinterventionsstudien zu unterstützen.
Kernaussagen
- 3.309 Neugeborene (1,3 %) hatten einen geeigneten Genotyp
- 1.149 Säuglinge wurden in die Studie eingeschlossen
- Der gesamte Ablauf lag median innerhalb der ersten 6 Lebenswochen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.10.2026. Verfasst von Annika Fehn und 19 weiteren Autor:innen. Beteiligte Einrichtung: Helmholtz Center Munich German Research Center for Environmental Health, Institute of Diabetes Research, Germany, Neuherberg. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Autoimmunity, Genetic Testing, Primary Prevention. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Leona M. and Harry B. Helmsley Charitable Trust.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Screening using polygenic risk scores can identify infants at increased risk for islet autoimmunity and type 1 diabetes. The Supplementation with B ifidobacterium infantis (EVC001) for Mitigation of Type 1 Diabetes Autoimmunity study is a primary prevention study that enrolled infants aged between 7 and 42 days with an elevated genetic risk for type 1 diabetes identified through newborn screening. Here, we describe the screening process that enabled timely genetic risk assessment and enrolment into the Supplementation with B. infantis (EVC001) for Mitigation of Type 1 Diabetes Autoimmunity clinical intervention study within the required enrolment window. Screening was conducted in Belgium, Germany, Poland, Sweden, and the United Kingdom. Among 257,784 screened newborns included in the analysis, 3,309 newborns (1.3%) had an eligible genotype associated with a>10% risk of developing early-stage type 1 diabetes by 6 years of age. Samples were collected at a median age of 2 days (interquartile range, 0–3), registered at a median age of 9 days (interquartile range, 6–11), and genotyped at a median age of 21 days (interquartile range, 18–24). Study sites received validated genotyping results at a median age of 22 days (interquartile range, 19–25). Consultation visits occurred at a median age of 29 days (interquartile range, 25–34) and enrolment into the Supplementation with B. infantis (EVC001) for Mitigation of Type 1 Diabetes Autoimmunity study took place at a median age of 38 days (interquartile range, 35–41). Overall, 1,149 eligible infants were enrolled into the Supplementation with B. infantis (EVC001) for Mitigation of Type 1 Diabetes Autoimmunity study (34.7% of eligible infants). These findings demonstrate the feasibility of accelerated genetic screening programs and show that newborn screening workflows can be completed within the first 6 weeks of life to support timely enrolment into early intervention trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Helmholtz Center Munich German Research Center for Environmental Health, Institute of Diabetes Research, Germany, Neuherberg.
- Technische Universität Dresden, Center for Regenerative Therapies, SN, Germany, Dresden.
- Technische Universität Dresden, Paul Langerhans Institut, Germany, Dresden.
- KU Leuven University Hospitals Leuven Gasthuisberg Campus, Department of Pediatrics, Flanders, Belgium, Leuven.
- KU Leuven, Department of Development and Regeneration, Flanders, Belgium, Leuven.
- Lund University, Unit for Pediatric Endocrinology, Department of Clinical Sciences Malmö, Skåne County, Sweden, Lund.
Förderung
- Leona M. and Harry B. Helmsley Charitable Trust
Zitieren
APA
Fehn, A., Bonifacio, E., Bonnin, E., Casteels, K., Gündert, M., Heigermoser, M., Jönsson, I., Kordonouri, O., Loff, A., Lundgren, M., Ołtarzewski, M., Owen, C., Robson, S., Roloff, F., Szypowska, A., Rochtus, A., Weiss, A., Winkler, C., Ziegler, A. G., & Haupt, F. (2026). Feasibility of Fast Turnaround Genetic Screening for Type 1 Diabetes Risk in Newborns – Recruiting Infants for the Global Platform for the Prevention of Autoimmune Diabetes Primary Prevention Study Supplementation with B ifidobacterium infantis for Mitigation of Type 1 Diabetes Autoimmunity. Hormone and Metabolic Research, 58(10), 391-398. https://doi.org/10.1055/a-2960-5380
Vancouver
Fehn A, Bonifacio E, Bonnin E, Casteels K, Gündert M, Heigermoser M, et al. Feasibility of Fast Turnaround Genetic Screening for Type 1 Diabetes Risk in Newborns – Recruiting Infants for the Global Platform for the Prevention of Autoimmune Diabetes Primary Prevention Study Supplementation with B ifidobacterium infantis for Mitigation of Type 1 Diabetes Autoimmunity. Hormone and Metabolic Research. 2026;58(10):391-398. doi:10.1055/a-2960-5380
BibTeX
@article{Fehn2026,
author = {Fehn, Annika and Bonifacio, Ezio and Bonnin, Elisa and Casteels, Kristina and Gündert, Melanie and Heigermoser, Martin and Jönsson, Ida and Kordonouri, Olga and Loff, Anja and Lundgren, Markus and Ołtarzewski, Mariusz and Owen, Catherine and Robson, Stephen and Roloff, Frank and Szypowska, Agnieszka and Rochtus, Anne and Weiss, Andreas and Winkler, Christiane and Ziegler, Anette-Gabriele and Haupt, Florian},
title = {Feasibility of Fast Turnaround Genetic Screening for Type 1 Diabetes Risk in Newborns – Recruiting Infants for the Global Platform for the Prevention of Autoimmune Diabetes Primary Prevention Study Supplementation with B ifidobacterium infantis for Mitigation of Type 1 Diabetes Autoimmunity},
journal = {Hormone and Metabolic Research},
year = {2026},
volume = {58},
number = {10},
pages = {391--398},
doi = {10.1055/a-2960-5380}
}
EUVIMED